In the last trading session, 1.63 million shares of the Verve Therapeutics Inc (NASDAQ:VERV) were traded, and its beta was 1.74. Most recently the company’s share price was $7.98, and it changed around -$0.18 or -2.21% from the last close, which brings the market valuation of the company to $675.62M. VERV currently trades at a discount to its 52-week high of $19.34, offering almost -142.36% off that amount. The share price’s 52-week low was $4.30, which indicates that the current value has risen by an impressive 46.12% since then. We note from Verve Therapeutics Inc’s average daily trading volume that its 10-day average is 1.4 million shares, with the 3-month average coming to 1.71 million.
Verve Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.40. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 2 recommended VERV as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Verve Therapeutics Inc is expected to report earnings per share of -0.67 for the current quarter.
Verve Therapeutics Inc (NASDAQ:VERV) trade information
Instantly VERV has showed a red trend with a performance of -2.21% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 8.77 on recent trading dayincreased the stock’s daily price by 9.01%. The company’s shares are currently up 41.49% year-to-date, but still up 6.12% over the last five days. On the other hand, Verve Therapeutics Inc (NASDAQ:VERV) is 32.78% up in the 30-day period. We can see from the shorts that 14.79 million shares have been sold at a short interest cover period of 10.17 day(s).
The consensus price target as assigned by Wall Street analysts is $14, which translates to bulls needing to increase their stock price by 43.0% from its current value. Analyst projections state that VERV is forecast to be at a low of $14 and a high of $14.
Verve Therapeutics Inc (VERV) estimates and forecasts
The year-over-year growth rate is expected to be 102.87%, up from the previous year.
Consensus estimates provided by 7 financial analysts predict the company will bring in an average of 4.24M in revenue for the current quarter. 5 analysts expect Verve Therapeutics Inc to make 3.79M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 5.14M and 5.7M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -17.60%. Forecasts for the next quarter put sales growth at -33.40%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -67.06%. Verve Therapeutics Inc earnings are expected to increase by 22.10% in 2025, but the outlook is positive 2.28% per year for the next five years.
VERV Dividends
Verve Therapeutics Inc’s next quarterly earnings report is expected to be released in March.
Verve Therapeutics Inc (NASDAQ:VERV)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 5.29% of Verve Therapeutics Inc shares, and 95.93% of them are in the hands of institutional investors. The stock currently has a share float of 101.29%. Verve Therapeutics Inc stock is held by 253.0 institutions, with ALPHABET INC. being the largest institutional investor. By 2024-06-30, it held 14.8546% of the shares, which is about 12.35 million shares worth $60.26 million.
BLACKROCK INC., with 7.9632% or 6.62 million shares worth $32.31 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
